Figure 4From: Adherence to treatment guidelines and survival in triple-negative breast cancer: a retrospective multi-center cohort study with 9156 patients Overall survival (OAS) and disease-free survival (DFS) for TNBC patients who received (versus those who did not receive) 100% guideline-adherent adjuvant treatment, as stratified by age (<50, 50–64, and ≥65) and adjusted for year of diagnosis, tumor size, grading, nodal status, menopausal status, and comorbidities. Back to article page